negative side effects of glp 1 agonists Part 2 a 3-Part Series; GLP-1 Medications for Weight Loss The cardiovascular effects of GLP-1

Semaglutide for the treatment of obesity

Long-acting GLP-1 receptor agonists improve glycemic control in type 2 diabetes patients while posing a low risk of hypoglycaemia due to their glucose-dependent mode of action

GLP-1 receptors are expressed in several key regions implicated in addiction and reward processing, including the ventral tegmental area (VTA), nucleus accumbens, amygdala, hippocampus, and lateral hypothalamus

Wegovy: May be covered to reduce cardiovascular risk in adults with heart disease who are overweight or obese, and for the liver condition MASH

Pharmacologic Treatment of Overweight and Obesity in Adults (MDText.com, 2021)

Between 0.6 and 1.8 percent of women and 0.3 and 0.7 percent of men worldwide are estimated to meet the criteria for the disorder